New drugs in essential thrombocythemia and polycythemia vera
- 31 March 1997
- journal article
- review article
- Published by Elsevier in Blood Reviews
- Vol. 11 (1) , 1-7
- https://doi.org/10.1016/s0268-960x(97)90001-1
Abstract
No abstract availableKeywords
This publication has 78 references indexed in Scilit:
- Natural leukocyte interferon-α therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-αAmerican Journal of Hematology, 1996
- Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyureaAmerican Journal of Hematology, 1996
- Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agentCancer, 1995
- A prospective comparison between treatment with phlebotomy alone and with interferon-alpha in patients with polycythemia veraAnnals of Hematology, 1994
- Sustained complete hematological remission in essential thrombocythemia after discontinuation of long-term α-IFN treatmentAnnals of Hematology, 1993
- Vascular complications of essential thrombocythaemia: a link to cardiovascular risk factorsBritish Journal of Haematology, 1993
- A long-term clinical trial of interferon alpha-therapy in essential thrombocythemiaAnnals of Hematology, 1992
- Interferon alpha-2b in the long-term treatment of essential thrombocythemiaAnnals of Hematology, 1991
- Maintenance therapy in the myeloproliferative disorders: the current optionsBritish Journal of Haematology, 1991
- Anagrelide: A New Drug for Treating ThrombocytosisNew England Journal of Medicine, 1988